The acting chair of the, Mark Uyeda, took the first step Tuesday to rolling back a rule that would require thousands of ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

It is one of three major Novartis products that are nearing the end of their patent lives, along with cancer drug Tasigna (nilotinib) and Promacta (eltrombopag) for thrombocytopaenia, which ...

Novartis India Ltd., incorporated in the year 1947, is a Small Cap company (having a market cap of Rs 2,146.62 Crore) operating in Pharmaceuticals sector. Novartis India Ltd. key Products/Revenue ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Novartis started a review of the business in ... including a limited number of upcoming generic launches and some big biosimilar products not due to reach the market until 2023 and 2024.

with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillationAcquisition adds a late-stage asset and is aligned with Novartis strategic focus ...

Novartis (NYSE:NVS – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating ...

CSL’s balance sheet is in sound condition. Financial risk is low given low revenue cyclicality and product demand is being largely driven by chronic indications. We forecast CSL’s net debt to EBITDA ...